Mintz represented Synnovation Therapeutics LLC, a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology, in connection with its definitive agreement with Novartis to acquire Synnovation’s wholly-owned subsidiary, Pikavation Therapeutics Inc., and its portfolio of pan mutant selective PI3Kα inhibitor programs, including its lead clinical asset SNV4818.  

SNV4818 is a potentially best in class pan mutant selective PI3Kα inhibitor currently in Phase 1/2 clinical trials for HR+/HER2  metastatic breast cancer and other solid tumors. It is designed to selectively target mutated PI3Kα while sparing the wild type enzyme, with the aim of improving tolerability and enabling more effective combination therapy strategies.  

Under the terms of the agreement, Synnovation will receive up to $3 billion in total cash consideration, consisting of $2 billion upfront and up to $1 billion in development, regulatory, and commercial milestone payments. The transaction is expected to close in the first half of 2026, subject to review under the Hart Scott Rodino Antitrust Improvements Act of 1976.  

Read Synnovation’s press release here. 

Goodwin Procter is serving as legal counsel to Synnovation, with Mintz also providing legal advice on key aspects of the transaction. The Mintz team was led by Ed Pease and included William Morrow, with support from Matthew T. Simpson.